

Silva Pharmaceuticals Limited

Un-Audited Financial Statements (Half Yearly)

For the Period from 01 July, 2020 to 31 December, 2020


SILVA PHARMACEUTICALS LTD.

Statement of Financial Position


As at 31 December, 2020

Particulars	Notes	Amount in Taka	
		31-Dec-20	30-Jun-20
ASSETS			
Non Current Assets		1,383,315,294	1,365,926,835
Property, Plant & Equipment	3.00	1,194,635,853	1,221,249,900
Intangible Assets	4.00	1,758,886	1,178,827
Right-of-use asset (ROU)	5.00	18,979,341	21,712,480
Capital work-in-Progress	6.00	167,941,214	121,785,628
Current Assets		1,182,198,252	1,090,279,961
Inventories	7.00	457,325,939	444,378,778
Trade and Other Receivables	8.00	269,735,042	263,426,843
Advances, Deposits and Prepayments	9.00	171,124,323	143,026,882
Fixed Deposits Receipts (FDR)		206,013,335	203,035,178
Cash and Cash Equivalents	10.00	77,999,613	36,412,280
Total Assets		2,565,513,546	2,456,206,796
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,272,239,841	2,198,109,877
Share Capital	11.00	1,365,000,000	1,365,000,000
Retained Earnings	12.00	907,239,841	833,109,877
Non-Current Liabilities		98,778,159	98,260,873
Deferred Tax Liabilities	13.00	86,627,963	84,977,387
Lease liabilities		12,150,196	13,283,486
Current Liabilities		194,495,546	159,836,046
Lease liabilities	14.00	4,122,545	5,722,394
Trade and Other Payables	15.00	6,977,721	6,542,477
Unclaimed Dividend Account		775,720	1,327,360
Short Term Loan		35,341,607	26,680,475
Provision for Expenses	16.00	147,277,953	119,563,340
Total Liabilities		293,273,705	258,096,919.0
Total Equity & Liabilities:		2,565,513,546	2,456,206,796
Net Assets Value (NAV) per share	23.00	16.65	16.10


The annexed notes (1-28) form an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: January 28, 2021

Silva Pharmaceuticals Ltd


Statements of Profit or Loss and Other Comprehensive Income


For the Half-Year ended 31 December, 2020


Particulars	Notes	Amount in Taka			
		Half-Yearly Results		Quarterly Results	
		01/07/2020 to 31/12/2020	01/07/2019 to 31/12/2019	01/10/2020 to 31/12/2020	01/10/2019 to 31/12/2019
Turnover	17.00	418,427,878	405,585,902	190,906,541	202,240,050
Cost of goods sold	18.00	(243,742,218)	(239,380,740)	(116,489,861)	(121,890,551)
Gross Profit		174,685,660	166,205,162	74,416,680	80,349,499
Operating expenses	19.00	(77,390,244)	(72,921,879)	(40,139,351)	(37,467,768)
Operating Income		97,295,416	93,283,283	34,277,329	42,881,730
Financial expenses		(1,351,566)	-	(669,527)	-
Net Operating Profit		95,943,850	93,283,283	33,607,802	42,881,730
Interest and Other income		7,578,426	12,387,560	3,780,853	6,508,592
Net Profit before Contribution to WPPF		103,522,276	105,670,843	37,388,655	49,390,323
Worker's Profit Participation fund (WPPF)	20.00	(4,929,632)	(5,031,945)	(1,780,412)	(2,351,920)
Net Profit before Income Tax		98,592,644	100,638,898	35,608,243	47,038,403
Income Tax Expenses:	21.00	(24,462,680)	(25,159,724)	(8,694,809)	(11,759,601)
Current Tax Expenses	21.01	(22,812,104)	(22,310,995)	(7,994,115)	(10,301,968)
Deferred Tax expenses	21.02	(1,650,576)	(2,848,729)	(700,694)	(1,457,633)
Net Profit after tax		74,129,964	75,479,174	26,913,434	35,278,802
Other Comprehensive Income		-	-	-	-
Total comprehensive income for the year		74,129,964	75,479,174	26,913,434	35,278,802
Earnings Per Share (EPS)	22.00	0.54	0.55	0.20	0.26

The annexed notes (1-28) form an integral part of these financial statements.


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;


Dated: January 28, 2021

SILVA PHARMACEUTICALS LTD.
Statement of Changes in Equity
For the Half-Year ended 31 December, 2020


Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2020	1,365,000,000	833,109,877	2,198,109,877
Net profit after tax during the period	-	74,129,964	74,129,964
Dividend Paid in Cash	-	-	-
Balance as at 31 December, 2020	1,365,000,000	907,239,841	2,272,239,841

For the Half-Year ended 31 December, 2019


Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2019	1,300,000,000	833,442,946	2,133,442,946
Net profit after tax during the period	-	75,479,174	75,479,174
Issue of Share Capital through Stock Dividend	65,000,000	(65,000,000)	-
Dividend Paid in Cash	-	(54,276,000)	(54,276,000)
Balance as at 31 December, 2019	1,365,000,000	789,646,120	2,154,646,120




Chairman




Managing Director



Director



Chief Financial Officer




Company Secretary


Place: Dhaka;

Dated: January 28, 2021

SILVA PHARMACEUTICALS LTD.**Statement of Cash Flows****For the Half-Year ended 31 December, 2020**


Particulars	Amount in Taka	
	01/07/2020 to 31/12/2020	01/07/2019 to 31/12/2019
Cash flows from Operating Activities		
Cash received from Customers	409,306,922	408,459,464
Cash received from non-operating income	10,391,183	14,538,438
Cash Paid to Suppliers	(231,701,684)	(210,170,363)
Cash Paid to Employees	(63,575,607)	(66,096,801)
Cash Paid for Others	(11,857,121)	(14,398,279)
Income Tax Paid	(19,932,749)	(18,977,455)
Net cash inflow/(outflow) from operating activities (A)	92,630,944	113,355,004
Cash flows from Investing Activities		
Acquisition of Property, Plant and Equipment	(6,486,295)	(25,673,965)
Cash Payments for Capital Work-in-progress	(46,155,586)	(25,529,401)
Cash received/Payments from/to FDR	(2,978,157)	(7,900,000)
Net cash used in investing activities (B)	(55,620,038)	(59,103,366)
Cash flows from Financing Activities		
Short Term Loan received/(Repaid)	8,661,132	-
Cash payment for Financial Expenses	(838,465)	-
Cash payment towards lease liabilities	(3,246,240)	-
Cash Dividend Paid	-	(54,276,000)
Net cash inflow from financing activities (C)	4,576,427	(54,276,000)
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)	41,587,333	(24,362)
Cash and Cash Equivalents at the beginning of the period	36,412,280	42,391,451
Cash and Cash Equivalents at the end of the period	77,999,613	42,367,089
Net Operating Cash Flow Per Share (NOCFPS) (Note-24.00)	0.68	0.83


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;

Dated: January 28, 2021